



(12) Translation of
european patent specification

(11) NO/EP 2694087 B1

NORWAY

(19) NO
(51) Int Cl.
A61K 38/13 (2006.01)
A61P 1/16 (2006.01)
A61P 31/14 (2006.01)
A61P 31/20 (2006.01)

Norwegian Industrial Property Office

(21)	Translation Published	2015.07.06
(80)	Date of The European Patent Office Publication of the Granted Patent	2015.01.28
(86)	European Application Nr.	12713680.2
(86)	European Filing Date	2012.03.30
(87)	The European Application's Publication Date	2014.02.12
(30)	Priority	2011.04.01, US, 201161470666 P
(84)	Designated Contracting States:	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
(73)	Proprietor	Novartis AG, Lichtstrasse 35, 4056 Basel, CH-Sveits
(72)	Inventor	NAOUMOV, Nikolai, c/o Novartis Pharma AGPostfach, CH-4002 Basel, CH-Sveits
(74)	Agent or Attorney	Zacco Norway AS, Postboks 2003 Vika, 0125 OSLO, Norge

(54)	Title	TREATMENT FOR INFECTION WITH HEPATITIS B VIRUS ALONE OR IN COMBINATION WITH HEPATITIS DELTA VIRUS AND ASSOCIATED LIVER DISEASES
(56)	References Cited:	WO-A1-2006/038088 INOUE KAZUAKI ET AL: "Evaluation of a cyclophilin inhibitor in hepatitis C virus-infected chimeric mice in vivo.", HEPATOLOGY (BALTIMORE, MD.) APR 2007 LNKD-PUBMED:17393519, vol. 45, no. 4, April 2007 (2007-04), pages 921-928, XP002680373, ISSN: 0270-9139 EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER: "EASL Clinical Practice Guidelines: Management of chronic hepatitis B", JOURNAL OF HEPATOLOGY, MUNKSGAARD INTERNATIONAL PUBLISHERS, COPENHAGEN, DK, vol. 50, no. 2, 1 February 2009 (2009-02-01), pages 227-242, XP025769996, ISSN: 0168-8278, DOI: 10.1016/J.JHEP.2008.10.001 [retrieved on 2008-10-29] cited in the application CHOKSHI S ET AL: "CHARACTERIZATION OF ANTIVIRAL ACTIVITIES OF CYCLOPHILIN INHIBITORS DEB025 (ALISPORIVIR) AND NIM811 ON HEPATITIS B VIRUS (HBV) REPLICATION AND HBSAG SECRETION IN VITRO", JOURNAL OF HEPATOLOGY, vol. 54, no. Suppl. 1, March 2011 (2011-03), pages S437-S438, XP002680374, & 46TH ANNUAL MEETING OF THE EUROPEAN-ASSOCIATION-FOR-THE-STUDY-OF-THE- LIVER (EASL); BERLIN, GERMANY; MARCH 30 -APRIL 03, 2011 ISSN: 0168-8278 PHILLIPS S ET AL: "ALISPORIVIR-INDUCED INHIBITION OF CELLULAR CYCLOPHILINS DISRUPTS HEPATITIS B VIRUS (HBV) REPLICATION IN VITRO AND IS SYNERGISTIC IN COMBINATION WITH DIRECT ANTIVIRAL TARGETING HBV-DNA POLYMERASE", JOURNAL OF HEPATOLOGY, vol. 56, no. Suppl. 2, April 2012 (2012-04), pages S199-S200, XP002680375, & 47TH ANNUAL MEETING OF THE EUROPEAN-ASSOCIATION-FOR-THE-STUDY-OF-THE- LIVER (EASL); BARCELONA, SPAIN; APRIL 18 -22, 2012 ISSN: 0168-8278 LOGUIDICE AMANDA ET AL: "Acetaminophen overdose-induced liver injury in mice is mediated

by peroxynitrite independently of the cyclophilin D-regulated permeability transition.",
HEPATOLOGY (BALTIMORE, MD.) 2 SEP 2011 LNKD- DOI:10.1002/HEP.24464
PUBMED:21626531, vol. 54, no. 3, 2 September 2011 (2011-09-02), pages 969-978,
XP002680376, ISSN: 1527-3350

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

Patentkrav

1. Alisporivir for bruk i behandlingen av hepatitt D-virusinfeksjon hos en pasient.

5 **2.** Alisporivir for bruk ifølge krav 1, hvori alisporivir administreres i kombinasjon med et direkte antiviralt middel.

10 **3.** Alisporivir for bruk ifølge krav 1, hvori det direkte antivirale middelet er valgt fra gruppen bestående hovedsakelig av telbivudin, lamivudin, emtricitabin, entecavir, adefovir og tenofovir.

4. Alisporivir for bruk ifølge krav 1 omfattende administrering av en effektiv mengde alisporivir og eventuelt administrering til pasienten av en interferon eller et direkte antiviralt middel.

15